---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-022439"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:48:17.488172+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Two Armistice Capital directors resign from Avalo board; CEO Garry Neil appointed Chairman

## Summary
- Steven Boyd and Keith Maher resigned effective August 8, 2022, not due to any disagreement with the company.
- Armistice Capital Master Fund irrevocably waived its right to appoint two directors to the board.
- CEO Garry Neil replaces Boyd as Chairman; Dr. Magnus Persson remains Lead Independent Director.
- Armistice's CIO expressed continued support for the company and its strategic progress.

## SEC filing metadata
- accession: 0001628280-22-022439
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/avtx-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-022439
- JSON: https://secwatch.observer/filing/0001628280-22-022439.json
- Plain text: https://secwatch.observer/filing/0001628280-22-022439.txt

## Key facts
- Executive change
  Garry Neil was appointed as Chairman of the Board at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: The Board appointed the Company’s President and Chief Executive Officer and Board member, Dr. Garry Neil, M.D., to replace Mr. Boyd as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm
- Executive change
  Keith Maher resigned as Director at Avalo Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm
- Executive change
  Steven Boyd resigned as Director at Avalo Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.